Eli Lilly has signaled a strategic move into the aesthetics space, with the company looking to add products targeting the body, skin and hair, Endpoints News reports.

The Indianapolis-based drugmaker has built its dermatology-adjacent credentials on the metabolic side of the market. Its incretin portfolio — tirzepatide, marketed as Zepbound for obesity and Mounjaro for type 2 diabetes — has already reshaped the body-contouring conversation in aesthetic clinics, as patients on GLP-1 therapies lose significant weight and often present with loose skin and volume shifts that drive demand for complementary procedures.

Now Lilly appears positioned to formalize its presence in aesthetics itself. According to Endpoints News, the company is exploring the addition of products spanning three categories: body, skin and hair. The report did not specify whether the strategy will rely on internal development, acquisitions, or licensing deals, and Lilly has not named any specific assets, formulations or device categories under consideration.

The move would place Lilly in direct competition with the established aesthetics incumbents — Allergan (AbbVie), Galderma, Merz and Johnson & Johnson's aesthetics franchise — companies that currently dominate the injectable neurotoxin and filler market alongside energy-based device makers.

For dermatology and aesthetic practices, a Lilly entry carries practical implications. The company's commercial infrastructure in metabolic disease gives it direct access to a patient population already primed for aesthetic intervention: GLP-1 users managing skin laxity, facial volume loss and other post-weight-loss concerns. An integrated offering that pairs pharmaceutical weight management with aesthetic products could shift how practices structure consultation and treatment pathways for this cohort.

Details on timeline, product categories in the pipeline and regulatory strategy remain undisclosed. Lilly has not confirmed the scope of the reported plans.

If Lilly converts this signal into a concrete portfolio, aesthetics practices could see a new competitive dynamic in a market that has been largely stable among its current major players — with the added variable of a competitor that already owns the prescribing relationship with millions of weight-management patients.